article thumbnail

ACS Fall 2023 First Disclosures  

Drug Hunter

The First Disclosures sessions at the 2023 ACS Fall Meeting in San Francisco, organized by Nikki Goodwin , presented a variety of new orally available small molecules. The post ACS Fall 2023 First Disclosures appeared first on Drug Hunter. Stay tuned!

article thumbnail

Molecules of the Month – August 2023

Drug Hunter

This month features many of the big reveals from the ACS fall 2023 first disclosures including Nurix’s BTK degrader and RAPT’s CCR4 autoimmune therapy. The post Molecules of the Month – August 2023 appeared first on Drug Hunter. Several of the molecules making the August list are in Ph.

article thumbnail

Molecules of the Month – July 2023

Drug Hunter

The post Molecules of the Month – July 2023 appeared first on Drug Hunter. KCL-286 – oral RARβ agonist efficacy data in Ph. I for spinal cord injury ligand-based virtual screen + opt from King’s College London.

Treatment 218
article thumbnail

Molecules of the Month – June 2023

Drug Hunter

The post Molecules of the Month – June 2023 appeared first on Drug Hunter. Sign up for our free weekly newsletter here to get more content like this straight to your inbox. Not a member? Request a trial to check out substructure search and more features.

article thumbnail

Must-See Sessions for ACS SF 2023

Drug Hunter

To help drug discovery professionals get the most out of your trip to ACS San Francisco 2023, we compiled a table of sessions that are likely to be of high interest to industry scientists here. BROWSE SESSIONS The post Must-See Sessions for ACS SF 2023 appeared first on Drug Hunter.

Drugs 130
article thumbnail

FDA Approved Oncology Drugs 2023

Crown Bioscience

In a significant development, the US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 55 new drugs in 2023. This marks the second-highest count in the past 30 years, with the highest being 59 new drug approvals in 2018 and represents an impressive 50% increase in drugs approved in 2022.

article thumbnail

Drug Hunter Journal Club: April 2023

Drug Hunter

27, 2023 [link] compound 3a caspase-6 IC 50 = 8 nM If you’re like many scientists who haven’t checked JACS every morning since leaving academia, you may have missed this interesting case study from Michelle Arkin and Adam Renslo’s teams at UCSF. Targeting a Caspase via a Non-Catalytic Cysteine Arkin and Renslo labs, UCSF J. already a member?

Drugs 133